“Disease is somatic , suffering from it, psychic …!!!”



At ESPERER Bioresearch Private Limited we aspire in our endeavour to become the most adaptable and altruistic company in anti-cancer therapy and related high-end healthcare space by bringing in the new concept of whole ecosystem under one roof in an innovative, cost effective way to serve even the unprivileged population across the globe. Our focus is treatment of cancer from early detection to full cure

ESPERER Bioresearch Private Limited, is committed to combining human values, ethics and the ancient Indian knowledge into bringing forth nutritional molecules with Customer first approach keeping the end user’s safety as the raison d’etre. Creating a knowledge pool across the oncology healthcare fraternity; with special focus on Cancer nutrition.
Our aim is to create and work towards a sustainable and dependable environs of advanced cancer treatment and services for the future. An altruistic vision with the best in medicine, nutrition, detection and treatment with the intervention of advanced genomics and result oriented participation of AI in the treatment of Cancer. Quite simply put it means we use science-based innovation to address our society’s most challenging healthcare issue. Making it affordable and also endeavouring to take it to the grassroot level to the underprivileged.

ESPERER stands for hope. And hope springs eternal in ESPERER as we step ahead in our endeavour to bring this hope in a scientific way to the patient, their family, their near and dear ones and the medical fraternity in general and the care giver and care acceptor in particular.

For a Cancer patient, HOPE is everything. Hope is not easily defined, but impossible to embrace without faith. For in reality hope always signifies that something better will come out of it.

ESPERER is focused on the very aspect of oncology: the medicine and molecules, the treatment and services during treatment, the help and support to the end user with a view of futuristic need for living a fulfilling life after being cured.



Global company with Competitive Advantage in Oncology…

Read More



To contribute to the enrichment of value addition among…

Read More



We are aimed to create new age supply chain practices to…

Read More


“Time has come to focus on Optimal Physical and Psycho-Social well-being of the patient in cancer therapy.”

/Director’s Desk

Cancer is one of the leading cause of death worldwide and considered as the second major cause of death after cardiovascular diseases.

The global anticancer drugs market is witnessing a significant growth and is expected to expand at substantial CAGR during the forecast period of 2017–2025. Factors such as the rising prevalence of cancer in many regions, rising awareness towards cancer diagnosis and treatment, introduction of novel pipeline drugs and therapies, rise in cancer awareness programs are expected to have a positive impact on the growth of global anticancer drugs market during the forecast period.

While the global burden of cancer continues to be high, therapeutic innovation based on improved understanding of disease biology and translational research has contributed to the changing paradigm of cancer treatment over the past two decades.

Cancer treatment has seen increased focus on personalized medicine, leading to patient segmentation based on biomarker status. The concept of personalized medicine is now an integral part of clinical practice in oncology, and more clinical trials are stratifying patient populations with predictive biomarkers; this has led to improved clinical outcomes by stratifying patients for their response to treatment. The trend of personalized medicine in oncology has had a positive impact on the drug development process.

Esperer Group is based on principle of “Employee first approach” and extremely dedicated to contribute in advanced Global cancer treatment arena.

Esperer management is well blend of expertise from backward API integration to formulation manufacturing to market faced sales & marketing skills. The team is extremely focused, knowledgeable and having deep aspiration to make a difference in life and society.

In India, we are working towards retaining and growing our position of market leadership in advanced key therapy areas with strong prescription driven hospital sales. We will continue to make considerable investments in product innovation to strengthen our pipeline of affordable niche products for Indian and international markets.

Our international markets now include several emerging country markets in Asia, Africa, South East Asia and part of Europe. We expect the international component of our business to grow significantly in width and depth in the years come.

We are going to be the first Indian company to bring “Cancer-Nutrition product formulation technology patent ” in coming days to improve quality of life of cancer patients as key thrust area in near future.

As employer I look to provide equal employment opportunity and believe in harnessing diversity in our organization. We provide professional development and career advancement to all our employees through our core values of fairness and meritocracy ensuring that we help our people grow with us. We aim to become a top Onco-pharmaceutical company with global-level capabilities serving the bigger need of humanity.

Cancer is one of the leading cause of death worldwide and considered as the second major cause of death after cardiovascular diseases.

The global anticancer drugs market is witnessing a significant growth and is expected to expand at substantial CAGR during the forecast period of 2017–2025. Factors such as the rising prevalence of cancer in many regions, rising awareness towards cancer diagnosis and treatment, introduction of novel pipeline drugs and therapies, rise in cancer awareness programs are expected to have a positive impact on the growth of global anticancer drugs market during the forecast period…

“We believe that ‘Limits exist only in the soul of those who do not Dream”

Read More


“Personalized Medicine” is our chance to revolutionize health care, but it will require a team effort by innovators, entrepreneurs, regulators, payers, and policymakers.

/Products & Services

Nutritional status is often jeopardized by the natural progression of neoplastic disease. (Refer to the Tumour-Induced Effects on Nutritional Status section.) Alterations in nutritional status begin at diagnosis, when psychosocial issues may also adversely affect dietary intake, and proceed through treatment and recovery. Esperer research team has developed a novel and comprehensive nutritional supplement that will provide all the required Nutrients in adequate quantities required for the effective management of Nutritional requirement during the course of the treatment and also to rebuild the body and maintain good health after the treatment is stopped, providing better immunity.

For more than two millennia, medicine has not wavered from its aspiration of being personalized. In ancient times, Hippocrates combined an assessment of the four humours—blood, phlegm, yellow bile, and black bile—to determine the best course of treatment for each patient. Today, the sequence of the four chemical building blocks that comprise DNA, coupled with telltale proteins in the blood, enable more accurate medical predictions. These include whether an individual is developing an illness now or will develop it many years in the future, will respond positively to treatment, or will suffer a serious reaction to a drug. But what is different about medicine today—and the reason the word “personalized” has been added for emphasis—is that technology has brought us much closer to exquisite precision in disease diagnosis and treatment.

Genomics is the study of all the genes of a cell, the DNA, mRNA and protein levels.As Genomics studies the entire genetic chain it is the most advanced diagnostic test available presently. Genomics is getting widely used in the leading institutes in field of cancer genetics testing and cancer genome testing across the world for treating diseases like cancer, heart disease, diabetes, neurological disorders, psychiatric disorders etc.

Genomics will help from being reactive to predictive mode of treatment.The key to effectively using clinical genomics to improve cancer treatment and outcomes lies in determining which sets of genes and gene interactions affect different subsets of cancers. The results of these genomic studies and research can then be used to develop clinically validated tests that provide the genomic profile of an individual's tumor, helping understand whether patients are likely to benefit from and respond to cancer therapies, or whether those patients are likely to experience a recurrence of their cancer.

Thus,while traditional drug discovery moves from “Target > Drug > Disease”, genomics moves from “Disease > Target > Mechanisms > Drugs” 

“Cancer is one of the world’s most urgent unmet medical needs.”

Helping people fight cancer is our passion. We are committed to help extend and improve the lives of people with cancer worldwide.

Product Pipeline

Product Pipeline

Coming Soon…




Read More


"Effectiveness without values is a tool without a purpose"

/Core Values

“In all our interactions, We will uphold the TRUST the customer has shown in approaching us at a crucial time. We will respond with integrity to ensure quickest access our QUALITY perception & in all our dealings, We will demonstrate HONESTY

Core values serve to constantly guide both the employee and the company in achieving their mutual goals, in a manner that is based on an ethical and ideological framework.

Integrity & Ethics

Simply put, the two principles of integrity and ethics translate into doing the right thing, in an honest, fair, and responsible way. Building your entire business on the foundation of honesty and integrity goes a long way into building a strong, trusting relationship with it’s employees, stakeholders, and customers. A truthful conduct on everyone’s part can create a strong, credible reputation of the company in the market, which is beneficial for everyone’s interests.

Respect for all

Respecting all employees means respecting their individual human rights and privacy, eliminating all kinds and forms of discrimination, whether based on religion, belief, race, ethnicity, nationality, gender or physical disability. Moreover, ensuring a safe and healthy workplace environment for all employees is an important part of giving respect to them.


Encouraging employees to take initiative and give the best. Adopting an error-embracing environment to empower employees to lead and make decisions.


Committing to great product, service, and other initiatives that impact lives within and outside the organization.


Taking a proactive stand to create and maintain a healthy work-life balance for workers.


/Esperer’s Knowledge Kiosk

ESPERER aims at comprehensive knowledge about cancer, its effect on people emotionally, financially and physically. If you are with ESPERER Bioresearch Private Limited, all these aspects are inculcated into making you the ultimate cancer care giver.

Multiple Myeloma
Multiple Myeloma
Lung Cancer
Lung Cancer

“Embrace the inner Entrepreneur in you, and give it Your Best….!!!”

/Working at Esperer

We make ESPERER a place to be proud of.

Esperer wants to be more productive and profitable, with the help of happy and positively engaged employees. Esperer strives for positive and happy people who are more likely to come up with a new idea or solve a complex problem that same day, but also can do so the next day. Creating a workplace filled with happy people isn’t as difficult for us. We know that work environment and culture coupled with the desire to do something positive to achieve the end result.

Apply Here



Name must not be empty
Please provide a valid Email
Message should not be empty
Message sent successfully!
Oops! Something went wrong try again!

Esperer BioResearch

Corporate Office

Esperer Bioresearch Pvt. Ltd.
4BA, 4th Floor, Gundecha Onclave
Khairani Road, Sakinaka, Mumbai. 400072

Distribution Office

Esperer Bioresearch Pvt Ltd. 123, First Floor, Satra Plaza Premises CHS Ltd. Plot no.19 & 20, Sec - 19D Vashi, Navi mumbai - 400705

Manufacturing Site

Plot No 107 A & B EPIP, Phase-1 Jharmajri, Baddi, Distt-Solan 174103 (HP) A WHO GMP Certified Site

Copyright © 2018 Esperer BioResearch. All rights reserved